CA2489244A1 - Traitement d'infections severes et de choc septique - Google Patents

Traitement d'infections severes et de choc septique Download PDF

Info

Publication number
CA2489244A1
CA2489244A1 CA002489244A CA2489244A CA2489244A1 CA 2489244 A1 CA2489244 A1 CA 2489244A1 CA 002489244 A CA002489244 A CA 002489244A CA 2489244 A CA2489244 A CA 2489244A CA 2489244 A1 CA2489244 A1 CA 2489244A1
Authority
CA
Canada
Prior art keywords
rtd
therapy
gram
lps
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002489244A
Other languages
English (en)
Inventor
Christoph Ladel
Ben Newton
Harald Labischinski
Nina Brunner
Christoph Gerdes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2489244A1 publication Critical patent/CA2489244A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation de rhésus-théta-défensine 1 (RTD-1) pour préparer un médicament pour assurer le traitement et/ou la prophylaxie de patients atteints d'affections sévères (bactériémies), choc septique compris.
CA002489244A 2002-06-13 2003-05-30 Traitement d'infections severes et de choc septique Abandoned CA2489244A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10226216.0 2002-06-13
DE10226216A DE10226216A1 (de) 2002-06-13 2002-06-13 Behandlung von schweren Infektionen und septischem Schock
PCT/EP2003/005694 WO2003105883A1 (fr) 2002-06-13 2003-05-30 Traitement d'infections severes et de choc septique

Publications (1)

Publication Number Publication Date
CA2489244A1 true CA2489244A1 (fr) 2003-12-24

Family

ID=29594458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002489244A Abandoned CA2489244A1 (fr) 2002-06-13 2003-05-30 Traitement d'infections severes et de choc septique

Country Status (5)

Country Link
EP (1) EP1523324A1 (fr)
AU (1) AU2003238175A1 (fr)
CA (1) CA2489244A1 (fr)
DE (1) DE10226216A1 (fr)
WO (1) WO2003105883A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732239A (zh) * 2011-06-02 2014-04-16 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119070B2 (en) 2002-04-30 2006-10-10 The Regents Of The University Of California Antimicrobial theta defensins, analogs thereof, and methods of use
EP1850861A1 (fr) * 2005-02-08 2007-11-07 Novozymes A/S Traitement par voie generale des infections a l'aide de defensines
US20170035845A1 (en) * 2015-08-07 2017-02-09 The Regents Of The University Of California Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression
MX2021015534A (es) * 2019-06-26 2022-04-20 The Univ Of Southern California Star Composiciones y metodos para el tratamiento de infecciones fungicas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335318B1 (en) * 1999-05-10 2002-01-01 The Regents Of The University Of California Antimicrobial theta defensins and methods of using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732239A (zh) * 2011-06-02 2014-04-16 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
CN109248310A (zh) * 2011-06-02 2019-01-22 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
US10603356B2 (en) 2011-06-02 2020-03-31 The Regents Of The University Of California Compositions and method for treatment of inflammatory bowel disease
CN109248310B (zh) * 2011-06-02 2022-07-01 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断

Also Published As

Publication number Publication date
EP1523324A1 (fr) 2005-04-20
WO2003105883A1 (fr) 2003-12-24
DE10226216A1 (de) 2003-12-24
AU2003238175A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
Sturm Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage
Wray et al. A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-α, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat
AU650262B2 (en) Compositions and methods for treating infections caused by organisms sensitive to beta -lactam antibiotics
US11752203B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
Xu et al. Interleukin‐33 contributes to ILC 2 activation and early inflammation‐associated lung injury during abdominal sepsis
Mikasa et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice
CN101018563A (zh) 衍生自cap18的抗菌肽
US20080234188A1 (en) Antimicrobial Peptides
Souza et al. Evaluation of the effects of ozone therapy in the treatment of intra-abdominal infection in rats
EP1691827B1 (fr) Utilisation des peptides derives de la chaine b beta du fibrinogene humaine pour le traitement du choc
BR112019018593A2 (pt) fagoterapia
CN116535481A (zh) 一种菲牛蛭抗菌肽rk22及其前体蛋白和应用
CN112341522A (zh) 一种抗菌肽及其应用
CA2489244A1 (fr) Traitement d'infections severes et de choc septique
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
Wu et al. Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages
Tellado et al. Critically III anergic patients demonstrate polymorphonuclear neutrophil activation in the intravascular compartment with decreased cell delivery to inflammatory focci
Koshak¹ et al. Causes of superinfections: deadly bacteria of tuberculosis
CN114478742B (zh) 一种抗幽门螺杆菌活性多肽及其应用
US20130231376A1 (en) Defensin-like molecules as novel antimicrobial agents
AU2003303953B2 (en) Antibacterial pyrazole carboxylic acid hydrazides
WEINSTEIN et al. Sulfonamide Blood Levels and Serum Antibacterial Activity: Studies of Relationships at Chemically Determined Blood Levels
US11161881B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
Watson The Surreptitious Survival of The Emerging Pathogen Staphylococcus lugdunensis in Macrophages Enhances S. aureus Infection

Legal Events

Date Code Title Description
FZDE Dead